cmAngio® vs VX1
AI Verdict
Choose cmAngio® if…
Choose cmAngio® if your primary goal is to leverage existing mammography data for early cardiovascular risk assessment in women. This AI software is ideal for non-invasively detecting Breast Arterial Calcifications (BAC) on mammograms, providing valuable insights into a patient's cardiovascular health without additional procedures or radiation exposure. It's best suited for integrating cardiovascular risk screening into routine breast imaging workflows.
View cmAngio® →Choose VX1 if…
Choose VX1 if you are a cardiac electrophysiologist seeking real-time, AI-guided assistance during atrial fibrillation and atrial tachycardia ablation procedures. This software is specifically designed to identify dispersed electrograms, helping to improve the precision and standardization of ablation outcomes. It's best utilized in the electrophysiology lab to enhance procedural efficiency and reduce inter-operator variability during live procedures.
View VX1 →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | cmAngio® | VX1 |
|---|---|---|
| Pricing | Paid, out-of-pocket | Contact for pricing |
| Deployment | Cloud-based, integrates with any DICOM-compliant viewer | Software integrated with existing electrophysiology (EP) lab mapping and recording systems. |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
cmAngio®Tool A (cmAngiou00ae) emphasizes quick installation (less than an hour) and broad compatibility with any DICOM-compliant viewer, suggesting straightforward integration into existing radiology workflows. While Tool B (VX1) offers a simple user interface for real-time identification, its integration is with specialized electrophysiology lab systems, which might imply a more complex setup for a niche environment.
Clinical Value
VX1Both tools offer significant clinical value. Tool A (cmAngiou00ae) provides valuable cardiovascular risk assessment by leveraging existing mammography data, aiding early detection. However, Tool B (VX1) offers real-time, AI-guided assistance during complex atrial fibrillation and tachycardia ablation procedures, directly impacting procedural success, reducing variability, and improving patient outcomes in a critical intervention, with supporting clinical evidence.
Pricing & Value
cmAngio®Both tools have opaque pricing, requiring direct vendor contact for details. However, Tool A (cmAngiou00ae) explicitly mentions the availability of 'limited-time offers for no-cost implementation and service,' which suggests a potentially lower barrier to entry or more flexible initial pricing options. This provides a slight advantage in perceived value and transparency regarding initial costs.
Enterprise Readiness
cmAngio®Tool A (cmAngiou00ae) explicitly states it is 'Cybersecure and HIPAA-compliant' and indicates that a Business Associate Agreement (BAA) can be obtained from the vendor, which are critical for enterprise adoption in healthcare. Tool B (VX1) does not explicitly state HIPAA compliance or BAA availability in the provided facts or search results, which is a significant gap for healthcare organizations needing to meet strict regulatory requirements.
Innovation
VX1Both tools represent innovative applications of AI in healthcare. Tool A (cmAngiou00ae) innovates by repurposing existing mammography images to provide new insights into cardiovascular risk. However, Tool B (VX1)'s real-time AI guidance during a complex, live interventional cardiac procedure demonstrates a higher degree of innovation in its immediate, dynamic application and integration into a critical surgical workflow.
Support & Docs
TieBoth tools provide evidence of existing documentation, with Tool A (cmAngiou00ae) mentioning an 'Operator's Manual' and Tool B (VX1) explicitly referring to a 'VX1TM SYSTEM USER MANUAL'. However, neither the provided facts nor the web search results offer specific details regarding customer support channels, service level agreements, or comprehensive training programs for either product.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | cmAngio® | VX1 |
|---|---|---|
| Tool Name | cmAngiou00ae | VX1 |
| Company | CureMetrix | Volta Medical |
| Description | FDA-cleared AI software for detecting Breast Arterial Calcifications (BAC) on mammograms, providing insights into cardiovascular health and aiding early risk assessment. | FDA-cleared AI software that assists cardiac electrophysiologists in real-time identification of dispersed electrograms during atrial fibrillation and atrial tachycardia ablation procedures. |
| Primary Specialty | Cardiology, Obstetrics & Gynecology, Radiology | Cardiology |
| Key Feature 1 | AI-based detection of Breast Arterial Calcifications (BAC) | AI-guided real-time identification of dispersed electrograms (EGMs) |
| Key Feature 2 | Processes both Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams | Assists cardiologists during AFib and atrial tachycardia ablation procedures |
Videos
Demos, reviews, and walkthroughs featuring cmAngio® and VX1.